NEW YORK (GenomeWeb News) – Thomson Reuters today said it and Orion Bionetworks are collaborating to elucidate the biological underpinnings of multiple sclerosis.

The collaboration also seeks to develop new therapies by generating predictive models of patient stratification and drug targets. Together, Thomson Reuters and Orion will combine their expertise and assets to "integrate and interpret clinical, molecular, imaging, and real-world patient data to develop new predictive models for" MS, Thomson Reuters said.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: swapping yeast genes with human orthologs to study conservation of function, and more.

Hong Kong is using DNA phenotyping to shame litterers.

A study appearing in Cell suggests some metastatic castration-resistant prostate cancer patients could benefit from PARP inhibitor therapy.

NIH's Francis Collins writes that scientific advances are poised to help populations all over the world, but more scientists are needed to keep the momentum.

May
28
Sponsored by
PerkinElmer

This online seminar will demonstrate how RNA-seq analysis in a model organism can provide insights into human disease. 

Jun
23
Sponsored by
PerkinElmer

This webinar will demonstrate how automated liquid handling workstations can reduce bottlenecks in library preparation for next-generation sequencing, enabling scientific advances in genomics research that were not possible five years ago.